MedTrace Logo

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

NCT05541328 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 169

Last updated 2022-09-15

No results posted yet for this study

Summary

This is a non-interventional, retrospective cohort study using the Flatiron Health Research Database (FHRD) and data from the single-arm phase II JULIET clinical trial (NCT02445248).

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

OTHER

Tisagenlecleucel

The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-03
Primary Completion
2021-02-05
Completion
2021-02-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05541328 on ClinicalTrials.gov